Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored. wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact StudyArticle Published on 2022-12-252023-07-11 Journal: Viruses [Category] COVID19(2023년), [키워드] adverse event COVID-19 reactogenicity vaccine. [DOI] 10.3390/v15010065 PMC 바로가기
Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trialsCOVID-19 환자의 결과에 대한 콜히친의 영향: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-12-012022-09-11 Journal: Annals of Medicine [Category] 임상, [키워드] 95% CI addition adverse event adverse events Clinical efficacy clinical outcomes ClinicalTrials Cochrane Library Colchicine control group COVID-19 database diarrhoea Effect higher risk hospital Hospital stay improve clinical outcome mean difference mechanical ventilation Meta-analysis Mortality no significant difference non-invasive ventilation non-invasive ventilation. not reduce Odds ratio outcome OVID Patient patients with COVID-19 Placebo placebos randomised controlled trial RCT RCTs receiving risk SARS-CoV-2 searched significant difference significantly higher standard treatment study group Support systematic review the study group Treatment Web of Science [DOI] 10.1080/07853890.2022.2096919 PMC 바로가기 [Article Type] Meta-Analysis
COVAD survey 2 long-term outcomes: unmet need and protocolArticle Published on 2022-12-012022-11-15 Journal: Rheumatology International [Category] 치료제, [키워드] adverse event antiviral drug approach approved Autoimmune diseases baseline booster doses cohorts COVID-19 COVID-19 infection COVID-19 vaccine disease Effect effort groups help Heterologous immune modulation Immunity IMPROVE long-term adverse effects pandemic protocol reduce registries risk syndrome synergistic Tolerability translation unmet need vaccination vaccination. Vaccine while [DOI] 10.1007/s00296-022-05157-6 PMC 바로가기
The associations between COVID-19 vaccination and psychological disorders among healthcare workers in ChinaArticle Published on 2022-12-012022-11-16 Journal: Journal of affective disorders [Category] COVID19(2023년), SARS, 치료기술, [키워드] adverse event analyzed Anxiety association caused China collected conducted Coverage COVID-19 COVID-19 vaccination COVID-19 vaccine cross-sectional DASS-21 Depression Factor healthcare healthcare worker incidence Logistic regression mean score nonparametric test participant Prevalence Psychological psychological disorder Psychological state Public Health Agency scored significantly higher significantly lower Sociodemographic characteristics Stress Stress Scale subgroups suffered the mean vaccination vaccination rate vaccination. Vaccines [DOI] 10.1016/j.jad.2022.08.080 PMC 바로가기
Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohortArticle Published on 2022-12-012022-11-16 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome adverse event adverse events Breakthrough infection China clinical manifestation Cohort collected concerning conducted coronavirus Coronavirus disease 2019 COVID-19 COVID-19 vaccination decrease Efficacy enrolled fatigue feature grade 3 higher risk inactivated Inactivated vaccine Infection infections liver liver dysfunction Liver transplantation Mild myalgia occurred omicron participant Patient patients postoperative protection rate. recipient retrospective cohort Retrospective study Safe safety profile SARS-CoV-2 Seven vaccination Vaccine variant viral shedding were infected whole-virion SARS-CoV-2 vaccine [DOI] 10.1080/22221751.2022.2136535 PMC 바로가기
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Safety of Remdesivir in 20 Children with COVID-19-Case Series-Article Published on 2022-12-012023-07-10 Journal: Biological & pharmaceutical bulletin [Category] COVID19(2023년), [키워드] adverse event Coronavirus disease 2019 pediatrics remdesivir. [DOI] 10.1248/bpb.b22-00470 PMC 바로가기
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIVHIV 보균자에서 비활성화된 SARS-CoV-2 백신의 안전성 및 면역원성Observational Study Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] adverse event age Analysis binding domain booster dose CD4 CD4 count CD4 counts Cell COVID-19 declined Efficacy enrolled evaluated Factor Frequency Gender geometric GMT healthy control healthy controls HIV humoral humoral immune response IgG immune immune response Immunocompromised in both groups inactivated Inactivated vaccine less MBC memory B occurred Patient PLWH predicted prospective observational study reduced remained reported response responses robust Safety Safety. SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event Seven significantly vaccination Viral load with HIV [DOI] 10.1080/22221751.2022.2059401 PMC 바로가기 [Article Type] Observational Study
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article